Li Jia-Qian, Zhao Rui-Xin, Yang Feng-Mei, Qi Xia-Ting, Ye Peng-Kun, Xie Meng
School of Pharmacy, Jiangsu University, 212013, China.
J Mater Chem B. 2022 Mar 23;10(12):2047-2056. doi: 10.1039/d1tb02522h.
Nano drug delivery systems are a research hotspot in the field of tumor therapy. In this work, molybdenum disulfide (MoS) nanosheets were selected as the base material and a natural red blood cell membrane (RBC membrane) was camouflaged on the nanosheets to enhance their dispersibility and tumor targeting profile. The camouflaged molybdenum disulfide nanocomposites (MoS-RBC) were successfully prepared by incubation. This nanomaterial has good stability and biocompatibility with a good immune evasion ability. MoS has a large specific surface area and unique layered structure, which provides favorable conditions for the loading of anticancer drugs. Adriamycin hydrochloride (DOX) was used as the model drug and the drug loading capacity was 98.98%. In the tumor microenvironment, the red cell membrane modified MoS drug delivery system (MoS-RBC-DOX) showed obvious pH-dependent release behavior. In addition, the excellent photothermal properties of MoS are conducive to the release of drugs, thus improving the efficacy. According to the cell tests, MoS-RBC had no cytotoxicity toward tumor cells, while DOX loading induced dose-dependent cytotoxicity. Furthermore, MoS-RBC has a favorable photothermal effect, and chemotherapy combined with photothermal therapy is more effective than any single therapy. fluorescence imaging and photothermal imaging experiments confirmed the promoted accumulation of carrier materials at the tumor site after RBC membrane modification. Finally, antitumor studies showed that photothermal/chemotherapy combined with MoS-RBC could completely inhibit tumor growth, and the body weights of mice fluctuated within the normal range without significant decrease. In summary, this MoS-RBC drug delivery system provides a safe, rapid and effective option for future treatment of breast cancer.
纳米药物递送系统是肿瘤治疗领域的一个研究热点。在本研究中，选择二硫化钼（MoS）纳米片作为基础材料，并在纳米片上伪装一层天然红细胞膜（RBC膜），以提高其分散性和肿瘤靶向性。通过孵育成功制备了伪装的二硫化钼纳米复合材料（MoS-RBC）。这种纳米材料具有良好的稳定性和生物相容性，以及良好的免疫逃逸能力。MoS具有较大的比表面积和独特的层状结构，为抗癌药物的负载提供了有利条件。以盐酸阿霉素（DOX）作为模型药物，载药量为98.98%。在肿瘤微环境中，红细胞膜修饰的MoS药物递送系统（MoS-RBC-DOX）表现出明显的pH依赖性释放行为。此外，MoS优异的光热性能有利于药物释放，从而提高疗效。根据细胞试验，MoS-RBC对肿瘤细胞无细胞毒性，而负载DOX则诱导剂量依赖性细胞毒性。此外，MoS-RBC具有良好的光热效应，化疗联合光热疗法比任何单一疗法都更有效。荧光成像和光热成像实验证实，红细胞膜修饰后载体材料在肿瘤部位的积累增加。最后，抗肿瘤研究表明，光热/化疗联合MoS-RBC可完全抑制肿瘤生长，小鼠体重在正常范围内波动，无明显下降。综上所述，这种MoS-RBC药物递送系统为未来乳腺癌治疗提供了一种安全、快速、有效的选择。
